These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

932 related items for PubMed ID: 18501070

  • 1. Cetuximab plus XELIRI or XELOX for first-line therapy of metastatic colorectal cancer.
    Moosmann N, Heinemann V.
    Clin Colorectal Cancer; 2008 Mar; 7(2):110-7. PubMed ID: 18501070
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M, Adenis A, Pignon JP, François E, Chauffert B, Ichanté JL, Boucher E, Ychou M, Pierga JY, Montoto-Grillot C, Conroy T.
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Recent results of irinotecan therapy in colorectal cancer].
    Láng I, Hitre E.
    Magy Onkol; 2004 Apr; 48(4):281-8. PubMed ID: 15655572
    [Abstract] [Full Text] [Related]

  • 5. Update on clinical data combining capecitabine with targeted agents in newly diagnosed colorectal cancer.
    Lee JJ, Chu E.
    Clin Colorectal Cancer; 2007 Dec; 7 Suppl 1():S16-20. PubMed ID: 18361802
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Current status of capecitabine in the treatment of colorectal cancer.
    Rothenberg ML.
    Oncology (Williston Park); 2002 Dec; 16(12 Suppl No 14):16-22. PubMed ID: 12520635
    [Abstract] [Full Text] [Related]

  • 10. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermüller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V.
    J Clin Oncol; 2011 Mar 10; 29(8):1050-8. PubMed ID: 21300933
    [Abstract] [Full Text] [Related]

  • 11. Dual biologic therapy in the first-line mCRC setting: implications of the CAIRO2 study.
    Chu E.
    Clin Colorectal Cancer; 2008 Jul 10; 7(4):226. PubMed ID: 18650190
    [No Abstract] [Full Text] [Related]

  • 12. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct 10; 19(109):219-24. PubMed ID: 21180382
    [Abstract] [Full Text] [Related]

  • 13. The role of new agents in the treatment of colorectal cancer.
    Folprecht G, Köhne CH.
    Oncology; 2004 Oct 10; 66(1):1-17. PubMed ID: 15031593
    [Abstract] [Full Text] [Related]

  • 14. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J, Hochster H.
    Colorectal Dis; 2003 Nov 10; 5 Suppl 3():1-9. PubMed ID: 23573555
    [Abstract] [Full Text] [Related]

  • 15. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M, Köhne CH, Schwartz GK, Vanhoefer U.
    Ann Oncol; 2003 Nov 10; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [Abstract] [Full Text] [Related]

  • 16. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome.
    García-Foncillas J, Díaz-Rubio E.
    Clin Transl Oncol; 2010 Aug 10; 12(8):533-42. PubMed ID: 20709651
    [Abstract] [Full Text] [Related]

  • 17. Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR study.
    Bennouna J, Borg C, Delord JP, Husseini F, Trillet-Lenoir V, Faroux R, François E, Ychou M, Goldwasser F, Bouché O, Senellart H, Kraemer S, Douillard JY.
    Clin Colorectal Cancer; 2012 Mar 10; 11(1):38-44. PubMed ID: 21803002
    [Abstract] [Full Text] [Related]

  • 18. Differences in efficacy and safety between capecitabine and infusional 5-fluorouracil when combined with irinotecan for the treatment of metastatic colorectal cancer.
    Montagnani F, Chiriatti A, Licitra S, Aliberti C, Fiorentini G.
    Clin Colorectal Cancer; 2010 Oct 10; 9(4):243-7. PubMed ID: 20920997
    [Abstract] [Full Text] [Related]

  • 19. Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancer.
    Cartwright T, Kuefler P, Cohn A, Hyman W, Berger M, Richards D, Vukelja S, Nugent JE, Ruxer RL, Boehm KA, Asmar L.
    Clin Colorectal Cancer; 2008 Nov 10; 7(6):390-7. PubMed ID: 19036692
    [Abstract] [Full Text] [Related]

  • 20. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
    Moosmann N, Heinemann V.
    Expert Rev Anticancer Ther; 2008 Mar 10; 8(3):319-29. PubMed ID: 18366281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 47.